Oncolytics Biotech (ONC) Sets New 1-Year Low at $2.20

Oncolytics Biotech, Inc. (TSE:ONC) hit a new 52-week low on Wednesday . The stock traded as low as C$2.20 and last traded at C$2.22, with a volume of 20914 shares. The stock had previously closed at C$2.27.

Separately, Royal Bank of Canada decreased their price objective on Oncolytics Biotech from C$10.00 to C$9.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th.

The firm has a market capitalization of $46.28 million and a price-to-earnings ratio of -2.50. The company has a debt-to-equity ratio of 13.67, a current ratio of 3.39 and a quick ratio of 3.14.

Oncolytics Biotech (TSE:ONC) last posted its earnings results on Friday, March 8th. The company reported C($0.28) earnings per share for the quarter. On average, analysts anticipate that Oncolytics Biotech, Inc. will post -0.769999996652174 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Oncolytics Biotech (ONC) Sets New 1-Year Low at $2.20” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.themarketsdaily.com/2019/05/24/oncolytics-biotech-onc-sets-new-1-year-low-at-2-20.html.

Oncolytics Biotech Company Profile (TSE:ONC)

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Further Reading: Stock Symbols and CUSIP Explained

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.